Menin inhibitors that target KMT2A-r acute leukemias are currently being studied, and revumenib was recently approved for relapsed/refractory (R/R) acute leukemias with KMT2A translocations in both adult and pediatric populations for AML, ALL, and MPAL.13 This evidence concerns the gene KMT2A and mixed phenotype acute leukemia.